top stories

Scoop: Af­ter pulling IPO am­bi­tions last De­cem­ber, Jeff Aron­in's Cas­tle Creek turns to pri­vate back­ers

Yesterday
Financing
Cell/Gene Tx

Pre­sent­ing a live End­points News event: Man­ag­ing a biotech in tur­bu­lent times

4 days ago
Bioregnum

Ather­sys tries to post-hoc-an­a­lyze its way out of an­oth­er tri­al fail for stroke stem cell ther­a­py

Yesterday
R&D
Cell/Gene Tx

Amid mon­key­pox fears, biotechs spring to ac­tion; Mod­er­na’s CFO trou­ble; Cuts, cuts every­where; Craft­ing the right ...

21 hours ago
Weekly

Latest

Most read

UP­DAT­ED: Flag­ship builds a new start­up out of pieces from 2 of its biotechs. And a Roche vet leaves to do some­thing ...

3 days ago
People
Startups

Sanofi and Re­gen­eron clear the fin­ish line in an in­flam­ma­to­ry esoph­a­gus dis­ease, leav­ing Take­da in the dust

Yesterday
Pharma
FDA+

Bi­par­ti­san trio of sen­a­tors ask FTC to look at PBMs and tac­tics to keep in­sulin prices high

Yesterday
Pharma

As mon­key­pox quick­ly spreads, a hand­ful of biotechs spring to ac­tion

Yesterday
Pharma

GSK re-ups menin­gi­tis B cam­paign with pop­u­lar ‘80s child ac­tor, now a mom of 4

Yesterday
Pharma
Marketing

Eu­rope to sus­pend about 100 gener­ic drugs af­ter un­cov­er­ing da­ta 'ir­reg­u­lar­i­ties' at In­di­an CRO

Yesterday
Pharma
see latest stream
People

French pres­i­dent names Stéphane Ban­cel a Cheva­lier for Mod­er­na's Covid tri­umph

Yesterday

Mod­er­na chair­man Noubar Afeyan de­fends vet­ting process in wake of CFO scan­dal — re­port

2 days ago

UP­DAT­ED: An­oth­er biotech that went pub­lic in pan­dem­ic boom aims to weath­er the bear mar­ket through R&D cut­backs

2 days ago
Financing

A new spin­out wades in­to ovar­i­an ag­ing, armed with a seed round and ex­per­i­men­tal drugs from Mass Gen­er­al

Yesterday

Mary­land of­fers loan to Clene de­spite ALS tri­al bumps

2 days ago

Not one, not two, but three — biotech claims it will pur­sue CARs T, M and NK all at once

2 days ago
Startups

Lo­cus pulls in a mod­est Se­ries B as it at­tempts to em­u­late on­col­o­gy's pre­ci­sion med­i­cine mod­el in an­tibac­te­ri­als

3 days ago

Chi­nese phar­ma gi­ant Hen­grui launch­es new com­pa­ny for glob­al­iza­tion play — with a Mer­ck KGaA vet at the helm

3 days ago

Star­na Ther­a­peu­tics emerges with fi­nanc­ing for mR­NA vac­cine and ther­a­pies

5 days ago
Deals

All Blue's $733M bid to ac­quire Zymeworks turns hos­tile as board bat­tles back — af­ter a biotech celebri­ty jumps in

Yesterday

Bay­er sounds re­treat from a $670 mil­lion CAR-T pact in the wake of a pa­tient death

2 days ago

Pfiz­er teams up with dig­i­tal ther­a­peu­tics part­ner for next prod­uct launch, this time in atopic der­mati­tis

2 days ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW
Subscribe to Endpoints News

Premium storiesSee all

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

5 days ago
People
Discovery

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at ...

Last week
Deals
R&D

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

Last week
People
AI

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

3 weeks ago
R&D

In FocusSee all

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

4 weeks ago
People
Discovery

'Em­pa­thy and love were not shown’: The sto­ry be­hind Taysha’s lay­offs, one of dozens of biotechs suf­fer­ing this ...

Last month
Cell/Gene Tx

Af­ter Covid-19 suc­cess, pa­tients with the world’s ‘most stig­ma­tized’ in­fec­tion push for their own Op­er­a­tion ...

Last month

Chirps, chats and Club­hous­es: First-time biotech founders turn to so­cial me­dia for ad­vice, in­vestors and re­cruit­ment

Last month
Startups

Don't missSee all

What drug cat­e­gories spend the most on ad­ver­tis­ing? Di­a­betes, pso­ri­a­sis and arthri­tis top the list

Yesterday
Pharma
Marketing

Flag­ship's Foghorn, part­nered with Mer­ck and Eli Lil­ly, gets a par­tial FDA hold af­ter pa­tient death

Yesterday
R&D
FDA+

Gilead leads HIV grant­mak­ers list, tops Gates Foun­da­tion in a first for an­nu­al sur­vey

2 days ago
Pharma
Marketing

Pfiz­er delves in­to di­ver­si­ty-fo­cused clin­i­cal tri­al part­ner­ship

2 days ago
Pharma

Endpoints Standouts

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

5 days ago
People
Discovery

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

Last month
Special

The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

3 months ago
Financing
Deals

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

5 months ago
People
Special

Peer review See all

May
20

Ex-Take­da ex­ec hits the ground run­ning at the helm of rare dis­ease biotech — with 3 pri­or­i­ties off the bat; ...

May
13

Hel­lo, I must be go­ing: Jorge Gomez is Mod­er­na CFO for on­ly a day; As set­backs mount, In­ovio’s Joseph Kim choos­es ...

May
6

With Aduhelm in tat­ters, the search is on for Michel Vounatsos' re­place­ment at Bio­gen; David Liu, Roger Perl­mut­ter ...

Apr
29

‘Nat­ur­al evo­lu­tion’: Caris­ma’s sci­en­tif­ic co-founder moves in­to the CSO post; Vas Narasimhan en­lists Ron­ny Gal ...

Apr
22

Mov­ing on from Us­ama Ma­lik's in­sid­er trad­ing im­broglio, Fore re­sets at the top; Take­da spin­out turns to Neu­rana CEO ...

Pharma channel feed

Yesterday

Fu­ji­film con­tin­ues its biotech build­ing spree with new fa­cil­i­ty in Chi­na

A Japan­ese con­glom­er­ate is mak­ing a big play in Chi­na with the open­ing of a new fa­cil­i­ty, as it con­tin­ues to ex­pand.

READ MORE

SQZ's out­side-the-box man­u­fac­tur­ing method slash­es pro­duc­tion time in ear­ly in study

2 days ago
Manufacturing

With new ac­qui­si­tion, Bo­ra to ven­ture in­to bi­o­log­ics

2 days ago
Manufacturing
latest in Pharma

Roche and blue­bird bio set­tle year-long trade­mark case, but keep qui­et on the de­tails

2 days ago
Law

Catal­ent in­tro­duces new AAV gene ther­a­py tech in aim to speed up man­u­fac­tur­ing process

2 days ago
Manufacturing

Covid-19 roundup: WHO val­i­dates an­oth­er shot; Ashish Jha chimes in on the state of vac­cines and ther­a­peu­tics

2 days ago
Coronavirus

With mon­key­pox cas­es ris­ing, one Eu­ro­pean coun­try is lock­ing down a small­pox vac­cine con­tract

2 days ago
Manufacturing

PhRMA's court win over HHS could be a boon for phar­ma pa­tient as­sis­tance pro­grams

3 days ago
Law
see latest stories

Marketing channel feed

4 days ago

Per­pet­u­al cri­sis? Phar­ma com­mu­ni­ca­tions and pub­lic re­la­tions pros just wait for the next shoe to drop

Wel­come to phar­ma pub­lic re­la­tions where every day feels like it might be a cri­sis.

READ MORE

J&J opens up con­ver­sa­tions around de­pres­sion in the LGBTQ+ com­mu­ni­ty with new cam­paign

3 days ago
Pharma

Ab­b­Vie ex­pands use of re­al pa­tients in lat­est Al­ler­gan Aes­thet­ics DTC cam­paign

3 days ago
Pharma
latest in Marketing

As new C. diff treat­ments prep for mar­ket, spe­cial­ists di­vid­ed on 'poop in a pil­l' or small mol­e­cule, study finds

4 days ago
Pharma

MRx roundup: Ho­log­ic en­lists Sh­eryl Crow for screen­ings; J&J Quick­Fire teams with feds for pub­lic health

4 days ago
Pharma

A long time com­ing: Glax­o­SmithK­line of­fi­cial­ly changes name to GSK

4 days ago
Pharma

Roche lays out ac­cess am­bi­tions in its ESG strate­gies, in­clud­ing in­no­va­tion and val­ue goals

5 days ago
Pharma

Strik­ing mu­rals in US cities high­light Hori­zon and Arthri­tis Foun­da­tion col­lab for gout aware­ness

Last week
Pharma
see latest stories

FDA+ channel feed

Yesterday

Try­ing to shake up the Parkin­son's par­a­digm, Ab­b­Vie sub­mits NDA for con­tin­u­ous, 24-hour in­fu­sion ther­a­py

Ab­b­Vie is ap­proach­ing the FDA with a new ther­a­py to po­ten­tial­ly treat Parkin­son’s dis­ease, us­ing pro­drugs of two med­ica­tions com­mon­ly used for the con­di­tion.

READ MORE

Sanofi's $20B buy­out of Gen­zyme pays off again with Eu­ro­pean OK for first Nie­mann-Pick drug

Yesterday

Proac­tive­ly pre­vent­ing short­ages: New FDA guid­ance spells out which drugs re­quire risk man­age­ment plans

2 days ago
Manufacturing
latest in FDA+

FDA com­mis­sion­er an­nounces new role for Janet Wood­cock, down­shift­ing away from drugs

2 days ago

House com­mit­tee unan­i­mous­ly ad­vances FDA user fee leg­is­la­tion with ac­cel­er­at­ed ap­proval tweaks

3 days ago

Sen­ate user fee reau­tho­riza­tion bill omits ac­cel­er­at­ed ap­proval re­forms, shows wide gaps with House ver­sion

4 days ago
Pharma

FDA lob­bies Con­gress over rare dis­ease court rul­ing with wide im­pli­ca­tions

4 days ago

Even FDA's Pe­ter Marks is wor­ried about the com­mer­cial vi­a­bil­i­ty of gene and cell ther­a­pies

4 days ago
Cell/Gene Tx
see latest stories

Manufacturing channel feed

3 days ago

Bavar­i­an Nordic se­cures BAR­DA con­tract for small­pox vac­cine

It seems that small­pox vac­ci­na­tion pro­duc­tion is weigh­ing on the mind of the US gov­ern­ment. And man­u­fac­tur­er Bavar­i­an Nordic is the lat­est com­pa­ny to ben­e­fit.

READ MORE

Long-ex­pect­ed UK lay­offs im­mi­nent for No­var­tis fol­low­ing sale

4 days ago
Pharma

Amidst R&D reshuf­fle, Ver­tex ex­pands its pres­ence in Boston, aim­ing to be­come num­ber one

4 days ago
R&D
latest in Manufacturing

Re­silience inks man­u­fac­tur­ing pact with ARCH-backed cell ther­a­py start­up as it preps for the long haul

2 days ago
Deals

A CRL lat­er, Gilead clears clin­i­cal hold on next-gen HIV drug — af­ter find­ing a new glass vial for it

4 days ago
FDA+

Emer­gent inks $225M cash small­pox deal as Chimerix im­plodes on re­org, FDA trou­ble

5 days ago
Pharma

UK gener­ics mak­er shut­ters, elim­i­nat­ing 1,000 jobs

Last week
Pharma

Bris­tol My­ers Squibb strikes deal to sell NY site to South Ko­re­an con­glom­er­ate — but it's keep­ing qui­et on the de­tails

Last week
Deals
Pharma
see latest stories